Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanif Esmail

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Elife|July 15, 2024
Anti-inflammatory therapy with nebulized dornase alfa for severe COVID-19 pneumonia: a randomized unblinded trialJoanna C Porter, Jamie Inshaw, Vincente Joel Solis, et al.
The Lancet. Respiratory Medicine|July 6, 2025
Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trialsRichard G White, Gavin J Churchyard, Katherine C Horton, et al.
Tuberculosis (Edinburgh, Scotland)|July 24, 2012
Detection and treatment of subclinical tuberculosisBrian D Robertson, Danny Altmann, Clif Barry, et al.
The Lancet. Global Health|January 20, 2023
A global core outcome measurement set for snakebite clinical trialsMichael Abouyannis, Hanif Esmail, Mainga Hamaluba, et al.
Medecine Tropicale Et Sante Internationale|December 14, 2023
[A global core outcome measurement set for snakebite clinical trials]Michael Abouyannis, Hanif Esmail, Mainga Hamaluba, et al.
BMJ Open|October 6, 2020
How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysisNick G Cunniffe, Simon J Gunter, Michael Brown, et al.
Medrxiv : the Preprint Server for Health Sciences|July 18, 2023
High resolution imaging and five-year tuberculosis contact outcomesHanif Esmail, Anna K Coussens, Friedrich Thienemann, et al.
The Lancet. Respiratory Medicine|March 26, 2026
PET-CT benchmarked detection and 5-year progression of asymptomatic tuberculosis: a longitudinal, prospective cohort studyHanif Esmail, Friedrich Thienemann, Bianca Sossen, et al.
The Lancet. Infectious Diseases|October 2, 2025
Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosisJames A Seddon, Jay Achar, Amyn A Malik, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Elife|July 15, 2024
Anti-inflammatory therapy with nebulized dornase alfa for severe COVID-19 pneumonia: a randomized unblinded trialJoanna C Porter, Jamie Inshaw, Vincente Joel Solis, et al.
The Lancet. Respiratory Medicine|July 6, 2025
Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trialsRichard G White, Gavin J Churchyard, Katherine C Horton, et al.
Tuberculosis (Edinburgh, Scotland)|July 24, 2012
Detection and treatment of subclinical tuberculosisBrian D Robertson, Danny Altmann, Clif Barry, et al.
The Lancet. Global Health|January 20, 2023
A global core outcome measurement set for snakebite clinical trialsMichael Abouyannis, Hanif Esmail, Mainga Hamaluba, et al.
Medecine Tropicale Et Sante Internationale|December 14, 2023
[A global core outcome measurement set for snakebite clinical trials]Michael Abouyannis, Hanif Esmail, Mainga Hamaluba, et al.
BMJ Open|October 6, 2020
How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysisNick G Cunniffe, Simon J Gunter, Michael Brown, et al.
Medrxiv : the Preprint Server for Health Sciences|July 18, 2023
High resolution imaging and five-year tuberculosis contact outcomesHanif Esmail, Anna K Coussens, Friedrich Thienemann, et al.
The Lancet. Respiratory Medicine|March 26, 2026
PET-CT benchmarked detection and 5-year progression of asymptomatic tuberculosis: a longitudinal, prospective cohort studyHanif Esmail, Friedrich Thienemann, Bianca Sossen, et al.
The Lancet. Infectious Diseases|October 2, 2025
Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosisJames A Seddon, Jay Achar, Amyn A Malik, et al.
Pageof 7